Listeria Monocytogenes Infections Treatment Market By Type Of Infection (Bacteremia, Meningitis, Brain Abscess, Gastroenteritis, Endocarditis, Pipeline Analysis) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

This report on global Listeria monocytogenes infections treatment market studies various drugs used for treatment of Listeria monocytogenes infection’s along with pipeline analysis of upcoming potential drugs. According to Centers for Disease Control and Prevention (CDC), Listeriosis, a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes, is an important public health problem in the United States. In addition, CDC estimates that approximately 1600 illnesses and 260 deaths due to listeriosis occur annually in the United States. Thus, drug pipeline of Listeria monocytogenes infections treatment market comprises potential drugs which are more target-specific and possess innovative properties. 

For the purpose of this study, the various infection types studied include bacteremia, meningitis, brain abscess, gastroenteritis, endocarditis, and others. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

 

Listeria Monocytogenes Infections Treatment Market

The pipeline analysis for Listeria monocytogenes infections treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Carbavance (The Medicines Company), Telavancin (Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin (Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global Listeria monocytogenes infections treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

For the purpose of this study, the global Listeria monocytogenes infections treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Listeria Monocytogenes Infections Treatment Market

North America was observed as the largest market for Listeria monocytogenes infections treatment in the base year 2015. Despite strict regulatory policies, L. monocytogenes still has a major detrimental influence in the food industry, causing food product recalls and disease outbreaks. According to a report published by United States Department of Agriculture (USDA) suggests that, every year approximately 48 million people become ill from foodborne illnesses in the United States. Even though just 1,600 people, on average, are sickened by foodborne Listeria, it ranks 3rd among causes of foodborne illness-associated deaths in the United States, causing nearly 19% of such deaths (255 in a typical year). It imposes an estimated USD 2.8 billion in economic burden in a typical year of which almost USD 2.1 billion is due to deaths. Rising prevalence of foodborne diseases, low grade sanity conditions at manufacturing site, improper storage and transportation of food materials and low awareness associated with the foodborne diseases in under developed and developing countries are the key factors assisting the market growth of Listeria monocytogenes infections treatment market globally during the forecast period 2016 – 2022.  

Choose License Type
Published Date:  May 2016
Category:  Pharmaceuticals
Report ID:   57831
Report Format:   PDF
Pages:   120
Rating:    4.1 (40)
Connect With Us
+1-408-641-3282
24/7 Research Support